Pulse Biosciences to Showcase nPulse Technology for Ventricular Arrhythmias at VT Symposium
Event summary
- Pulse Biosciences will present preclinical data on nPulse endocardial catheters for ventricular arrhythmias at the 21st Annual International VT Symposium on October 10, 2026.
- The presentation, titled 'Recent Advances in PFA of Ventricular Arrhythmias,' will be delivered by Jacob Koruth, MD.
- The event takes place at the New York Marriott at the Brooklyn Bridge.
- Pulse Biosciences' nsPFA technology aims to non-thermally clear cells while sparing adjacent tissue.
The big picture
Pulse Biosciences' presentation at the VT Symposium highlights its push into ventricular arrhythmia treatment, an expansion from its existing focus on atrial fibrillation. The company's nsPFA technology represents a novel approach in cardiac ablation, potentially offering advantages over thermal methods. Success in this space could significantly broaden Pulse Biosciences' market opportunity in the growing electrophysiology market.
What we're watching
- Clinical Translation
- Whether preclinical results will translate into successful human clinical studies for ventricular arrhythmias.
- Market Expansion
- The pace at which Pulse Biosciences can expand its nsPFA technology into new cardiac indications.
- Competitive Positioning
- How Pulse Biosciences' non-thermal ablation approach differentiates it from existing ventricular arrhythmia treatments.
Related topics